Page last updated: 2024-11-07

pilocarpine and Presbyopia

pilocarpine has been researched along with Presbyopia in 16 studies

Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.

Presbyopia: The normal decreasing elasticity of the crystalline lens that leads to loss of accommodation.

Research Excerpts

ExcerptRelevanceReference
"To present a case series of retinal detachments associated with the use of pilocarpine for presbyopia."8.12Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia. ( Al-Khersan, H; Flynn, HW; Townsend, JH, 2022)
"Pilocarpine plasma levels were assessed in approximately 10% of enrolled participants."7.30Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study. ( El-Harazi, SM; Kannarr, S; Kim, JL; Lievens, C; Liu, H; Moshirfar, M; Peace, JH; Robinson, MR; Safyan, E; Zheng, S, 2023)
"This special commentary reviews the treatment of presbyopia with a focus on the recently approved medication Vuity (pilocarpine 1."6.82Pilocarpine 1.25% and the changing landscape of presbyopia treatment. ( Ho, AC; Lee, JK; Meghpara, BB; Mian, SI; Rapuano, CJ, 2022)
"To present a case series of retinal detachments associated with the use of pilocarpine for presbyopia."4.12Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia. ( Al-Khersan, H; Flynn, HW; Townsend, JH, 2022)
" Safety measures included adverse events."3.11Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. ( Gore, A; Guo, Q; Liu, H; McCabe, C; Moshirfar, M; Price, FW; Robinson, MR; Safyan, E; Waring, GO; Wirta, D, 2022)
"This special commentary reviews the treatment of presbyopia with a focus on the recently approved medication Vuity (pilocarpine 1."2.82Pilocarpine 1.25% and the changing landscape of presbyopia treatment. ( Ho, AC; Lee, JK; Meghpara, BB; Mian, SI; Rapuano, CJ, 2022)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19903 (18.75)18.7374
1990's0 (0.00)18.2507
2000's4 (25.00)29.6817
2010's0 (0.00)24.3611
2020's9 (56.25)2.80

Authors

AuthorsStudies
Waring, GO1
Price, FW1
Wirta, D1
McCabe, C1
Moshirfar, M2
Guo, Q1
Gore, A1
Liu, H2
Safyan, E2
Robinson, MR2
Al-Khersan, H1
Flynn, HW1
Townsend, JH1
Meghpara, BB1
Lee, JK1
Rapuano, CJ1
Mian, SI1
Ho, AC1
Westheimer, G1
Amarikwa, L1
Michalak, SM1
Caul, S1
Mruthyunjaya, P1
Rahimy, E1
Mansoori, T1
Kannarr, S1
El-Harazi, SM1
Lievens, C1
Kim, JL1
Peace, JH1
Zheng, S1
Tucker, T1
Early, J1
Ostrin, LA1
Glasser, A2
Koeppl, C1
Findl, O1
Kriechbaum, K1
Drexler, W1
Liu, DT1
Hon, C1
Lam, DS1
Chan, WM1
Wendt, M1
Croft, MA1
McDonald, J1
Kaufman, PL1
Abramson, DH1
Franzen, LA1
Coleman, DJ1
Ichikawa, H1
Suzumura, A1
Taniguchi, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants With Presbyopia[NCT03804268]Phase 3323 participants (Actual)Interventional2018-12-21Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.25

Visual acuity for near (40 cm) target was measured in mesopic conditions. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 0.25)

Interventionletters correctly read (Least Squares Mean)
Vehicle3.7
Pilocarpine HCl Ophthalmic Solution6.3

Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.5

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. Mixed effect model for repeated measures (MMRM) was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 0.5)

Interventionletters read correctly (Least Squares Mean)
Vehicle4.2
Pilocarpine HCl Ophthalmic Solution9.3

Change From Baseline in Photopic, High-contrast, Binocular Distance-corrected Intermediate Visual Acuity (DCIVA) Letters at Day 30, Hour 3

Visual acuity for intermediate (66 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionletters read correctly (Least Squares Mean)
Vehicle3.1
Pilocarpine HCl Ophthalmic Solution6.6

Mean Change From Baseline in Mesopic Near Vision Presbyopia Task-based Questionnaire (NVPTQ) Performance Score at Day 30, Hour 3

NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close,1=poor,2=fair,3=good,4=very good,5=excellent;impact of squinting on performance as 0=No,I did not squint, 1=Yes,squinting helped me read some/all text, 2=Yes,but I still could not read any of the text; and satisfaction as 0=very dissatisfied to 4=very satisfied. The score based on vision related ability and impact of squinting=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses), total possible score of 0-5. Higher scores=better outcomes;positive change from Baseline=improved performance(reading ability). (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle0.6
Pilocarpine HCl Ophthalmic Solution1.4

Mean Change From Baseline in Mesopic NVPTQ Satisfaction Score at Day 30, Hour 3

NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close to 5=excellent; impact of squinting on performance as 0=No, I did not squint, 1=Yes, squinting helped me read some/all text, 2=Yes, but I still could not read any of the text; and satisfaction as 0=very dissatisfied,1=dissatisfied,2=neither satisfied nor dissatisfied,3=satisfied, 4=very satisfied. The score based on satisfaction items=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses) for a total possible score of 0 to 4. Higher scores=better outcomes; a positive change from Baseline=higher satisfaction. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle0.6
Pilocarpine HCl Ophthalmic Solution1.4

Mean Change From Baseline in PICQ Impact Score at Day 30, Hour 3

PICQ had 20 questions about impact experienced by participants due to their problems seeing up over past 7 days. PICQ Impact domain had 6 items: Item 9:Rely on others,15:rest eyes,16:Feel older,17:Feel self-conscious,19:Take longer to complete a task,20:Inconvenient. First 5 impacts items included response categories: 0=never to 4=all the time. Item 20 had response categories: 0=not at all to 4=extremely. Item 9 included an additional response category with a value of 9 to indicate question was not applicable to participant and the responses were assigned missing values. PICQ Impacts Score=[(Item9+Item15+Items16,17Testlet+Item19+Item20)/(nonmissing responses to 5 components of impacts score)] where Items 16,17 Testlet=(Item16+Item17)/non-missing responses to Items 16 and 17. PICQ Impact score ranges from 0 to 4; with 0=least amount of impacts to 4=greatest amount of impacts. Higher scores correspond to poorer outcomes. A negative change from Baseline=improvement. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle-0.4
Pilocarpine HCl Ophthalmic Solution-0.7

Mean Change From Baseline in Presbyopia Impact and Coping Questionnaire (PICQ) Coping Score at Day 30, Hour 3

PICQ=20 questions about impact experienced by participants due to their problems over past 7 days.PICQ Coping domain had 8 items: 1:Normal-sized text,2:Small-sized text,3:Information on a computer,4:Information on a cell phone,5:Increase font size,6:Use glasses to read close,12:Hold reading materials farther out/closer,13:Squint to read. Each item had response categories:0=never to 4=all the time. Items 3, 4, 5, and 6 had additional response categories with values of 9/10 to indicate the question is not applicable to participant and were assigned missing values.PICQ Coping Score:(Item 1,2 Testlet+Item 3,4 Testlet+Item 5+Item 6+Item 12+Item 13)/non-missing responses to the 6 components of coping score where Items 1,2 Testlet=(Item1+Item2)/non-missing responses to Items 1,2;Items 3,4 Testlet=(Item3+Item4)/non-missing responses to Items 3, 4. Score ranges:0=to least amount of coping to 4=greatest amount of coping. Higher scores=poorer outcome; a negative change from Baseline=improvement. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle-0.5
Pilocarpine HCl Ophthalmic Solution-1.0

Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 1

Visual acuity for near (40 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. (NCT03804268)
Timeframe: Day 30 (Hour 1)

Interventionpercentage of participants (Number)
Vehicle73.9
Pilocarpine HCl Ophthalmic Solution92.5

Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 3

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. (NCT03804268)
Timeframe: Day 30 (Hour 3)

Interventionpercentage of participants (Number)
Vehicle71.9
Pilocarpine HCl Ophthalmic Solution84.5

Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3

Visual acuity for near (40 centimeters (cm)) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter (cd/m^2) measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionpercentage of participants (Number)
Vehicle8.1
Pilocarpine HCl Ophthalmic Solution30.7

Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 6

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 6)

Interventionpercentage of participants (Number)
Vehicle8.8
Pilocarpine HCl Ophthalmic Solution18.4

Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 10

Visual acuity for near (40cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast, binocular DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day1) to Day 30 (Hour 10)

Interventionpercentage of participants (Number)
Vehicle8.6
Pilocarpine HCl Ophthalmic Solution7.5

Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 8

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 8)

Interventionpercentage of participants (Number)
Vehicle8.5
Pilocarpine HCl Ophthalmic Solution10.6

Reviews

1 review available for pilocarpine and Presbyopia

ArticleYear
Pilocarpine 1.25% and the changing landscape of presbyopia treatment.
    Current opinion in ophthalmology, 2022, Jul-01, Volume: 33, Issue:4

    Topics: Humans; Myopia; Pilocarpine; Presbyopia; Vision, Ocular

2022

Trials

3 trials available for pilocarpine and Presbyopia

ArticleYear
Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
    JAMA ophthalmology, 2022, 04-01, Volume: 140, Issue:4

    Topics: Color Vision; Female; Humans; Male; Pilocarpine; Presbyopia; Treatment Outcome; Visual Acuity

2022
Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
    American journal of ophthalmology, 2023, Volume: 253

    Topics: Double-Blind Method; Humans; Pilocarpine; Presbyopia; Refraction, Ocular; Visual Acuity

2023
[A study on the effects of pilocarpine in low concentration on various ophthalmic functions especially on the AC-A ratio].
    Nihon ganka kiyo, 1971, Volume: 22, Issue:4

    Topics: Accommodation, Ocular; Adenine Nucleotides; Adult; Age Factors; Clinical Trials as Topic; Female; Hu

1971

Other Studies

12 other studies available for pilocarpine and Presbyopia

ArticleYear
Vuity - pilocarpine ophthalmic solution for presbyopia.
    The Medical letter on drugs and therapeutics, 2022, Feb-07, Volume: 64, Issue:1643

    Topics: Accommodation, Ocular; Administration, Ophthalmic; Eye; Humans; Muscarinic Agonists; Ophthalmic Solu

2022
Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia.
    American journal of ophthalmology, 2022, Volume: 242

    Topics: Humans; Male; Middle Aged; Miotics; Pilocarpine; Presbyopia; Retinal Detachment; Retinal Diseases; R

2022
Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes?
    Optometry and vision science : official publication of the American Academy of Optometry, 2022, 08-01, Volume: 99, Issue:8

    Topics: Accommodation, Ocular; Humans; Miosis; Ophthalmic Solutions; Pilocarpine; Presbyopia; Pupil

2022
Vitreofoveal Traction Associated With Pilocarpine for Presbyopia.
    Ophthalmic surgery, lasers & imaging retina, 2022, Volume: 53, Issue:7

    Topics: Female; Humans; Pilocarpine; Presbyopia; Retinal Diseases; Tomography, Optical Coherence; Traction;

2022
Pilocarpine 1.25% for the treatment of presbyopia.
    Indian journal of ophthalmology, 2023, Volume: 71, Issue:1

    Topics: Accommodation, Ocular; Humans; Lens, Crystalline; Pilocarpine; Presbyopia

2023
Pilocarpine 1.25% Ophthalmic Solution (Vuity) for the Treatment of Presbyopia.
    American family physician, 2023, Volume: 107, Issue:6

    Topics: Humans; Ophthalmic Solutions; Pilocarpine; Presbyopia; Time Factors

2023
Accommodation measurements in a prepresbyopic and presbyopic population.
    Journal of cataract and refractive surgery, 2004, Volume: 30, Issue:7

    Topics: Accommodation, Ocular; Adult; Diagnostic Techniques, Ophthalmological; Eye Color; Humans; Middle Age

2004
Comparison of pilocarpine-induced and stimulus-driven accommodation in phakic eyes.
    Experimental eye research, 2005, Volume: 80, Issue:6

    Topics: Accommodation, Ocular; Adult; Anterior Chamber; Ciliary Body; Humans; Lenses, Intraocular; Middle Ag

2005
Accommodation measurements in prepresbyopic and presbyopic populations.
    Journal of cataract and refractive surgery, 2005, Volume: 31, Issue:9

    Topics: Accommodation, Ocular; Diagnostic Techniques, Ophthalmological; Humans; Miotics; Pilocarpine; Presby

2005
Lens diameter and thickness as a function of age and pharmacologically stimulated accommodation in rhesus monkeys.
    Experimental eye research, 2008, Volume: 86, Issue:5

    Topics: Accommodation, Ocular; Aging; Animals; Lens, Crystalline; Macaca mulatta; Miotics; Monkey Diseases;

2008
Pilocarpine in the presbyope. Demonstration of an effect on the anterior chamber and lens thickness.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1973, Volume: 89, Issue:2

    Topics: Aged; Anterior Chamber; Biometry; Humans; Lens, Crystalline; Middle Aged; Pilocarpine; Presbyopia; T

1973
[Accommodation in presbyopics influenced by aging and extensive medication].
    Nihon ganka kiyo, 1971, Volume: 22, Issue:1

    Topics: Accommodation, Ocular; Adult; Aging; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Piloca

1971